ArticleBMC cancer2025
Elevated expression of CK19, Ki67, and β-Catenin as prognostic biomarkers in hepatocellular carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCytokeratin 19 (CK19), Ki67 antigen (Ki67), and β-catenin are abnormally overexpressed in hepatocellular carcinoma (HCC), but their diagnostic and prognostic value remains unclear. This study aims to investigate the predictive role of these three markers in post-operative survival of HCC patients.
methodsThe expression levels of CK19, Ki67, and β-catenin in HCC tumor tissues were determined through public datasets. Kaplan-Meier survival analysis and multivariate Cox regression were performed to evaluate their prognostic value. Immunohistochemistry and Western blotting were used to detect the expression levels of CK19, Ki67, and β-catenin in hepatocellular carcinoma tissues and adjacent non-cancerous tissues. Transcriptome sequencing was performed to analyze the differential transcriptional changes between HCC and adjacent non-cancerous tissues. A cohort of HCC post-operative patients was included to analyze the correlation between the three markers and clinical pathological features.
resultsCK19, Ki67, and β-catenin were highly expressed in HCC tissues and lowly expressed in adjacent non-cancerous tissues. High expression of CK19, Ki67, and β-catenin was closely associated with poor disease-free survival (DFS) and overall survival (OS) in HCC patients' post-surgery. These three markers serve as independent prognostic factors for DFS and OS. Immunohistochemistry and Western blotting revealed upregulation of CK19, Ki67, and β-catenin in HCC tissues, while transcriptome sequencing indicated alterations related to metabolic reprogramming, immune evasion, and invasion/metastasis in HCC. Clinical data from HCC patients showed that CK19 expression correlated with tumor number and differentiation grade, Ki67 expression correlated with patient age, tumor size, tumor number, lymphatic metastasis, and tumor differentiation, while β-catenin expression was closely related to tumor diameter, number, and capsule status.
conclusionCK19, Ki67, and β-catenin are highly expressed in HCC and can serve as molecular markers for post-operative recurrence and poor survival in HCC patients, providing a basis for precise prognostic evaluation in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.